Therapeutic effects and safety of apatinib mesylate on patients with gastric carcinoma peritoneal metastasis in SOX scheme.

OBJECTIVE The aim of this study was to investigate the diagnostic values of serum tumor markers in gastric carcinoma peritoneal metastasis and the therapeutic efficacy as well as safety of apatinib mesylate combined with Geo+Oxaliplatin (SOX) scheme treatment in gastric carcinoma peritoneal metastasis. PATIENTS AND METHODS Sixty patients with gastric carcinoma peritoneal metastasis and 11 patients without gastric carcinoma peritoneal metastasis were selected as the research subjects. The levels of serum tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125, CA211, CA242, CA724, and CA19-9] and abdominal irrigating solution exosome [micro ribonucleic acid (miR)-21 and miR-320c] and the differences in their diagnostic values were compared and analyzed. The patients with gastric cancer peritoneal metastases are then divided into two groups, one for control (30 cases receiving just SOX scheme treatment) and the other for the experiment (30 cases receiving SOX scheme treatment plus apatinib mesylate). Besides, the differences in serum tumor marker level, therapeutic efficacy, overall survival (OS), complication rating, and Quality of Life Questionnaire-Core-30 (QLQ-C30) score among patients after treatment were compared. RESULTS Demonstrated that serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125, CA211, CA242, CA724, and CA19-9 levels of patients in the transfer group were remarkably enhanced compared with those of patients in the non-transfer group, and the levels of abdominal irrigating solution exosome (miR-21 and miR-320c) were reduced compared with those in non-transfer group (p<0.05). The area under the curve (AUC) of the diagnosis of gastric carcinoma peritoneal metastasis by each index were 0.553, 0.880, 0.832, 0.619, 0.863, 0.651, 0.918, and 0.903, respectively. Patients in the experimental group's serum levels of CEA, CA125, CA211, CA242, CA724, and CA19-9 were noticeably lower after therapy compared to those in the control group, and their median OS was also noticeably longer (p<0.05). After treatment, the objective remission rate (ORR) and disease control rate (DCR) of the control group and experimental group amounted to 6.7% vs. 30.0% and 50.0% vs. 86.7%, respectively. ORR and DCR of the experimental group were notably higher (p<0.05). Between the patients in the control group and the experimental group, there were no glaring variations in the frequency of problems (hypertension, nausea, vomiting, bone marrow suppression, hand-foot syndrome, and leucopenia) (p>0.05). The cognitive function, emotional function, and life health scores of patients in the experimental group were significantly higher than those in the control group (p<0.05), which suggested that serum tumor markers and miR-21 as well as miR-320c showed high diagnostic efficiency in gastric carcinoma peritoneal metastasis. CONCLUSIONS Apatinib mesylate combined with SOX scheme treatment was more effective in treating gastric carcinoma peritoneal metastasis and possessed the same safety as single SOX scheme treatment. Hence, it is worthy of clinical promotion.

[1]  H. Arslan,et al.  Periprosthetic infection risks and predictive value of C-reactive protein / albumin ratio for total joint arthroplasty , 2021, Acta bio-medica : Atenei Parmensis.

[2]  P. Eysel,et al.  Periprosthetic Infection in Joint Replacement. , 2017, Deutsches Arzteblatt international.

[3]  Zong-ke Zhou,et al.  The influence of body mass index on the outcomes of primary total knee arthroplasty , 2015, Knee Surgery, Sports Traumatology, Arthroscopy.

[4]  J. Callés-Escandon,et al.  Increased Glycemic Variability Is Independently Associated With Length of Stay and Mortality in Noncritically Ill Hospitalized Patients , 2013, Diabetes Care.

[5]  J. Parvizi,et al.  The effect of malnutrition on patients undergoing elective joint arthroplasty. , 2013, The Journal of arthroplasty.

[6]  Seung-Baik Kang,et al.  Relations between Long-term Glycemic Control and Postoperative Wound and Infectious Complications after Total Knee Arthroplasty in Type 2 Diabetics , 2013, Clinics in orthopedic surgery.

[7]  A. Exadaktylos,et al.  Characteristics, symptoms, and outcome of severe dysnatremias present on hospital admission. , 2012, The American journal of medicine.

[8]  E. Larson,et al.  The Role of Pre-Operative and Post-Operative Glucose Control in Surgical-Site Infections and Mortality , 2012, PloS one.

[9]  A. Eskelinen,et al.  Obesity, diabetes, and preoperative hyperglycemia as predictors of periprosthetic joint infection: a single-center analysis of 7181 primary hip and knee replacements for osteoarthritis. , 2012, The Journal of bone and joint surgery. American volume.

[10]  K. Ikari,et al.  Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs , 2011, Modern rheumatology.

[11]  R. Rosenthal,et al.  Glycemic Control and Infections in Patients with Diabetes Undergoing Noncardiac Surgery , 2011, Annals of surgery.

[12]  S. Chillag,et al.  Perioperative Management of Diabetes and Hyperglycemia in Patients Undergoing Orthopaedic Surgery , 2010, The Journal of the American Academy of Orthopaedic Surgeons.

[13]  T. Moilanen,et al.  Preoperative hyperglycemia predicts infected total knee replacement. , 2010, European journal of internal medicine.

[14]  T. Vail,et al.  The impact of glycemic control and diabetes mellitus on perioperative outcomes after total joint arthroplasty. , 2009, The Journal of bone and joint surgery. American volume.

[15]  R. Pietrobon,et al.  The impact of diabetes on perioperative patient outcomes after total hip and total knee arthroplasty in the United States. , 2008, The Journal of arthroplasty.

[16]  M. Kuzuya,et al.  Prognostic value of serum albumin combined with serum C-reactive protein levels in older hospitalized patients: continuing importance of serum albumin , 2006, Aging clinical and experimental research.

[17]  M. Larkin.  Software , 2003, The Lancet.

[18]  B. Razavi,et al.  Exclusion criteria , 2000, The Lancet.

[19]  F. Brancati,et al.  Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. , 1999, Diabetes care.

[20]  P. McLardy-Smith,et al.  Prosthetic joint infection , 1999, Current infectious disease reports.

[21]  K. Greene,et al.  Preoperative nutritional status of total joint patients , 1991 .

[22]  K. Dhital,et al.  Is low serum albumin associated with postoperative complications in patients undergoing oesophagectomy for oesophageal malignancies? , 2015, Interactive cardiovascular and thoracic surgery.

[23]  H. Scharf,et al.  [Risk profiling of postoperative complications in 17,644 total knee replacements]. , 2006, Der Unfallchirurg.

[24]  K. Greene,et al.  Preoperative nutritional status of total joint patients. Relationship to postoperative wound complications. , 1991, The Journal of arthroplasty.